0001415889-24-002161.txt : 20240201 0001415889-24-002161.hdr.sgml : 20240201 20240201160009 ACCESSION NUMBER: 0001415889-24-002161 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240131 FILED AS OF DATE: 20240201 DATE AS OF CHANGE: 20240201 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LILLY ENDOWMENT INC CENTRAL INDEX KEY: 0000316011 ORGANIZATION NAME: STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-06351 FILM NUMBER: 24586811 BUSINESS ADDRESS: STREET 1: 2801 NORTH MERIDIAN STREET CITY: INDIANANAPOLIS STATE: IN ZIP: 46208 BUSINESS PHONE: 3179245471 MAIL ADDRESS: STREET 1: 2801 NORTH MERIDIAN ST CITY: INDIANAPOLIS STATE: IN ZIP: 46208 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ELI LILLY & Co CENTRAL INDEX KEY: 0000059478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 350470950 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: LILLY CORPORATE CTR STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 BUSINESS PHONE: 3172762000 MAIL ADDRESS: STREET 1: LILLY CORPORATE CENTER STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 FORMER COMPANY: FORMER CONFORMED NAME: LILLY ELI & CO DATE OF NAME CHANGE: 19941024 4 1 form4-02012024_040201.xml X0508 4 2024-01-31 0000059478 ELI LILLY & Co LLY 0000316011 LILLY ENDOWMENT INC 2801 NORTH MERIDIAN STREET INDIANAPOLIS IN 46208-0068 false false true false 0 Common Stock 2024-01-31 4 S 0 35506 645.282 D 99376877 D Common Stock 2024-01-31 4 S 0 9169 646.41 D 99367708 D Common Stock 2024-01-31 4 S 0 8696 647.532 D 99359012 D Common Stock 2024-01-31 4 S 0 7424 648.598 D 99351588 D Common Stock 2024-01-31 4 S 0 4931 649.803 D 99346657 D Common Stock 2024-01-31 4 S 0 815 650.729 D 99345842 D Common Stock 2024-01-31 4 S 0 900 651.56 D 99344942 D Common Stock 2024-01-31 4 S 0 1900 654.252 D 99343042 D Common Stock 2024-01-31 4 S 0 2750 655.265 D 99340292 D Common Stock 2024-01-31 4 S 0 1700 656.302 D 99338592 D Common Stock 2024-01-31 4 S 0 600 657.398 D 99337992 D Common Stock 2024-01-31 4 S 0 1700 658.651 D 99336292 D Common Stock 2024-01-31 4 S 0 797 659.64 D 99335495 D Common Stock 2024-01-31 4 S 0 985 661.088 D 99334510 D Common Stock 2024-01-31 4 S 0 200 661.63 D 99334310 D Common Stock 2024-01-31 4 S 0 500 662.808 D 99333810 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $645.00 to $645.95, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), and (15) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $646.00 to $646.99, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $647.07 to $648.0202, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $648.115 to $649.11, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $649.185 to $650.00, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $650.235 to $651.00, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $651.3174 to $651.83, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $653.765 to $654.76, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $654.765 to $655.60, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $655.86 to $656.635, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $656.98 to $657.87, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $658.11 to $658.94, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $659.185 to $660.0675, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $660.5246 to $661.23, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $662.65 to $663.025, inclusive. /s/ Diane M. Stenson, Vice President & Treasurer, on behalf of Lilly Endowment Inc. 2024-02-01